BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Melodic Combination d: A Survey of \Unrecorded Music Energy\ Show- Improving as a Cook: Culinary Experiences in the Kitchen
- Must-See Attractions in Australia
- Nations for Youngsters to Visit
- The Main 20 Photography Instagram Records to Follow
- Bolsonaro says hallucinatory effects of meds made him tamper with ankle tag
- 5 Great Home Remodel Administrations With Green Arrangements In 2024
- 5 Breakout Stars in Late television Series
- The Most Encouraging New companies to Look Out For
